Regarding safety, cemiplimab’s adverse event (AE) profile was manageable and consistent with those established among PD-1 ...
At the molecular level, transcriptomic profiling of a single nucleus RNA-seq dataset of renal epithelial cells revealed ...
The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...
A recent clinical trial found that transplantation in lower-risk myelodysplastic syndrome (MDS) patients with high-risk ...
MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...
To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...
Patients enrolled had NET liver metastases of any grade or origin that were progressive, symptomatic, or represented a high ...
The US FDA has approved the supplemental new drug application (sNDA) for revumenib (Revuforj) in the treatment of relapsed or ...
Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...
The US FDA has granted fast track designation to the novel amanitin-based antibody-drug conjugate (ADC) pamlectabart ...
A panelist discusses how early relapse and prognostic indicators shape second-line therapy selection and emerging treatment ...
El-Khoueiry, MD, an associate professor of clinical medicine in the Division of Medical Oncology and director of the phase I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback